Petros PharmaceuticalsPTPI -2.15% EPS without NRI is $-1.60 as of Mar. 2026. Among 787 Drug Manufacturers companies, Petros Pharmaceuticals ranks better than 95.17% on this metric.
Petros Pharmaceuticals's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $-0.03.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.60.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 77.50% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 64.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Petros Pharmaceuticals's EPS without NRI or its related term are showing as below:
PTPI'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 29.1 Med: 45.7 Max: 77.5
Current: 77.5
During the past 7 years, Petros Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 77.50% per year. The lowest was 29.10% per year. And the median was 45.70% per year.
PTPI's 3-Year EPS without NRI Growth Rate is ranked better than 95.17% of 787
companies
in the Drug Manufacturers industry
Industry Median: 9.7
vs PTPI: 77.50
Petros Pharmaceuticals (OTCPK:PTPI) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Petros Pharmaceuticals EPS without NRI Related Terms
Petros Pharmaceuticals EPS without NRI Historical Data
* Premium members only.
The historical data trend for Petros Pharmaceuticals's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTPI vs STEK, KOAN, GCAN: EPS without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's PE Ratio without NRI falls into.
Petros Pharmaceuticals EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.60
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals (PTPI) has a EPS without NRI of $-1.60 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Petros Pharmaceuticals and its competitors. According to the industry distribution chart, Petros Pharmaceuticals ranks #38 out of 787 companies in the Drug Manufacturers industry, placing it in the top 4.8%.
Is Petros Pharmaceuticals' EPS without NRI too high?
Petros Pharmaceuticals' current EPS without NRI is $-1.60. Based on the distribution chart, Petros Pharmaceuticals ranks #38 out of 787 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Petros Pharmaceuticals' EPS without NRI compare to STEK and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #38 out of 787 companies for EPS without NRI. This places Petros Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current EPS without NRI is $-1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current EPS without NRI of $-1.60. The current EPS without NRI is $-1.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current EPS without NRI is $-1.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 